Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Revenue (2022 - 2025)

Axsome Therapeutics' Revenue history spans 4 years, with the latest figure at $196.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 65.03% year-over-year to $196.0 million; the TTM value through Dec 2025 reached $638.5 million, up 65.55%, while the annual FY2025 figure was $638.5 million, 65.55% up from the prior year.
  • Revenue for Q4 2025 was $196.0 million at Axsome Therapeutics, up from $171.0 million in the prior quarter.
  • Across five years, Revenue topped out at $196.0 million in Q4 2025 and bottomed at $8.8 million in Q2 2022.
  • The 4-year median for Revenue is $90.9 million (2023), against an average of $94.9 million.
  • The largest annual shift saw Revenue skyrocketed 429.48% in 2023 before it fell 20.7% in 2024.
  • A 4-year view of Revenue shows it stood at $24.4 million in 2022, then skyrocketed by 193.5% to $71.5 million in 2023, then surged by 66.04% to $118.8 million in 2024, then skyrocketed by 65.03% to $196.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Revenue are $196.0 million (Q4 2025), $171.0 million (Q3 2025), and $150.0 million (Q2 2025).